Table 2.
Progression-free survival rate age at 3 and at 6 months, the mean and median number of treatment cycles received, the parametric description of survival with the lognormal distribution, and average survival times. The estimated average survival time with the lognormal distribution is calculated by exp (μ + σ2/2).
| Progression-free survival | L-Sarcoma | Non-L-sarcoma | |||
|---|---|---|---|---|---|
| Trabectedin | Ifosfamide | Trabectedin | Ifosfamide | ||
| PFS probability (%) | At 3 months | 59.5 | 47.4 | 37.5 | 51.6 |
| At 6 months | 41.7 | 15.8 | 18.8 | 22.6 | |
| N treatment cycles | Mean | 6.1 | 3.8 | 3.8 | 3.4 |
| Median | 6 | 4 | 3 | 3 | |
|
| |||||
| Parametric analysis of survival | |||||
| PFS | μ | 1.50 | 1.08 | 1.00 | 1.20 |
| σ | 1.05 | 1.05 | 1.04 | 1.04 | |
| Average PFS | In months | 7.75 | 5.07 | 4.64 | 5.71 |
| In years | 0.65 | 0.42 | 0.39 | 0.48 | |
| OS | μ | 2.42 | 2.15 | 1.77 | 2.21 |
| σ | 1.00 | 1.00 | 0.94 | 0.94 | |
| Average OS | In months | 18.58 | 14.17 | 9.09 | 14.18 |
| In years | 1.55 | 1.18 | 0.76 | 1.18 | |
PFS: progression-free survival; OS: overall survival.